Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
British Columbia
-
Victoria, British Columbia, Canada, V8R 1J8
- Vancouver Island Health Authority
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Saint John Regional Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 4K4
- Dalhousie MS Research Unit
-
Sydney, Nova Scotia, Canada, B1P 1P3
- Cape Breton Regional Hospital
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Gatineau, Quebec, Canada, J9J 0A5
- Clinique Neuro-Outaouais
-
Greenfield Park, Quebec, Canada, J4V 2J2
- Neuro Rive-Sud
-
Montreal, Quebec, Canada, H2L 4M1
- CHUM - Hopital Notre Dame
-
Montreal, Quebec, Canada, H3A 2B4
- McGill University - MNI
-
Sherbrooke, Quebec, Canada, J1H 5N4
- CHUS - Hôpital Fleurimont
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Key Inclusion Criteria:
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent.
- Documented diagnosis of Relapsing Multiple Sclerosis (McDonald 2010 Criteria).
- Must have an Expanded Disability Status Scale (EDSS) score from 0 to 4.0, inclusive.
- Must satisfy the approved therapeutic indications for Tysabri as per Product Monograph.
- Must either be treatment naïve or have been treated with disease modifying therapy DMT(s) (such as, but not limited to, Avonex, Betaseron, Rebif, Copaxone, Extavia, Tecfidera and/or Gilenya) for ≤5 years total prior to date of informed consent.
- Decision to treat with Tysabri must precede enrollment.
Key Exclusion Criteria:
- Any prior treatment with Tysabri.
- Contraindications to treatment with Tysabri as described in the Product Monograph.
- History of progressive multifocal leukoencephalopathy (PML) or other opportunistic infections, or an increased risk for such infections.
- History of diagnosis of Primary Progressive Multiple Sclerosis [PPMS] and/or Secondary Progressive Multiple Sclerosis [SPMS].
- Receiving immunomodulatory or immunosuppressive therapy.
- Prior history of immunosuppressive use (mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate, cladribine, rituximab).
- Immunocompromised at the time of enrollment.
- Known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible).
- Women breastfeeding, pregnant, or planning to become pregnant; women who are not post-menopausal or surgically sterile who are unwilling to practice contraception.
- Inability to comply with study requirements.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29)
Time Frame: Baseline, Months 12 and 24
|
The 29-item Multiple Sclerosis Impact Scale (MSIS-29) is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items.
The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health.
|
Baseline, Months 12 and 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Annualized Relapse Rate
Time Frame: Baseline, Months 12 and 24
|
A clinical relapse is defined as new or recurrent neurological symptoms, not associated with fever, lasting for at least 24 hours, and followed by a period of 30 days of stability or improvement.
|
Baseline, Months 12 and 24
|
|
Change from Baseline in Expanded Disability Status Scale (EDSS)
Time Frame: Baseline, Months 12 and 24
|
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability.
Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
|
Baseline, Months 12 and 24
|
|
Change from Baseline in Work Productivity and Activity Impairment
Time Frame: Baseline, Months 12 and 24
|
The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities.
The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
Baseline, Months 12 and 24
|
|
Change from Baseline in EuroQol 5-Dimension (EQ-5D)
Time Frame: Baseline, Months 12 and 24
|
The EQ-5D is a self-administered questionnaire consisting of 5 sets of 3 questions pertaining to specific health states (i.e., mobility, self-care, pain, usual activities, anxiety), and a visual analog scale that records the respondent's self-rated health from 0 (worst imaginable health state) to 100 (best imaginable health state).
|
Baseline, Months 12 and 24
|
|
Change from Baseline in Patient Global Assessment of Wellbeing Visual Analog Scale
Time Frame: Baseline, Months 12 and 24
|
Patient Global Assessment of Wellbeing measures quality of life on a 100 mm Visual Analog Scale (VAS) where 0 is the worst imaginable health state and 100 is the best imaginable health state.
|
Baseline, Months 12 and 24
|
|
Percentage of participants with Clinical Disease-Free Status
Time Frame: Baseline, Months 12 and 24
|
Freedom from clinical disease activity is defined as the percentage of participants with no relapse and no EDSS progression, defined as a 1-point change from baseline.
EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability.
Scoring is based on measures of impairment in eight functional systems on examination by a neurologist.
|
Baseline, Months 12 and 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Biogen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAN-TYS-12-10333
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.